Lincosamide and glycopeptide antibiotics

Current antibiotics have largely contributed to the substantial increase in the longevity of human since their discovery because these antibiotics possess adverse and specific activity against fatal bacteria. In spite of our strong inventory of antimicrobial medications, the controversy against certain microorganisms is still prevailing. Antibiotics offer a robust challenge to bacteria, but on the other hand, extensive use causes development of resistance, which renders the more extensively utilized antibiotics useless over the time. This exhaustive challenge induces new antibiotics to tackle the resistance issue. This development has also wiped out several initial antibiotic classes, threatening to obliterate β-lactams, and is still approaching the final stronghold of medically efficient antibacterial drugs, glycopeptide and lincosamide antibiotics. This chapter describes important developments in the field of novel synthetic technology, chemical structure, action mechanisms, bacterial resistance, and biological activities of glycopeptide and lincosamide antibiotics. The only glycopeptide antibiotics suitable for human being usage are teicoplanin and vancomycin. Clindamycin, which is a semisynthetic chlorinated variant of lincomycin, is a commonly employed antibiotic in medical care. Both bacteriostatic antibiotics moderate the formation of protein in susceptible bacteria; yet, they could be effective at higher amounts. In this chapter, the chemistry, microbial activity, as well as medication of glycopeptide and lincosamide antibiotics are elaborated along with their future aspects.